Literature DB >> 11148472

Multiple primary melanomas.

J J Stam-Posthuma1, C van Duinen, E Scheffer, J Vink, W Bergman.   

Abstract

BACKGROUND: Patients with clinically diagnosed dysplastic nevi or a family history of melanoma with or without histologically diagnosed dysplastic nevi seem to be at higher risk for the development of multiple melanomas.
OBJECTIVE: Our purpose was to determine which factors increased the risk for the development of subsequent melanomas.
METHODS: This was a retrospective study in 56 patients with 157 melanomas.
RESULTS: Early age at onset (58.9%), clinically diagnosed dysplastic nevi (82.0%), a histologically diagnosed dysplastic nevus (64%), family history of clinically diagnosed dysplastic nevi (70.8%) or melanoma (64.7%) and a histologically diagnosed dysplastic nevus in combination with a family history of melanoma (48%) were found in a high percentage of patients. The mean age at diagnosis was 38.2 years. The mean interval between the first and second melanoma was 34.3 months. Of the second melanomas, 76.8% developed in a different anatomic region from the first melanomas. The mean tumor thickness (Breslow) decreased from 1.11 mm for the first melanomas to 0.90 mm for the second melanomas.
CONCLUSION: The results suggest that genetic factors might be involved in a certain subset of patients in whom melanomas develop early and successively.

Entities:  

Mesh:

Year:  2001        PMID: 11148472     DOI: 10.1067/mjd.2001.110878

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  Ambient UV, personal sun exposure and risk of multiple primary melanomas.

Authors:  Anne Kricker; Bruce K Armstrong; Chris Goumas; Melisa Litchfield; Colin B Begg; Amanda J Hummer; Loraine D Marrett; Beth Theis; Robert C Millikan; Nancy Thomas; Hoda Anton Culver; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Peter A Kanetsky; Klaus Busam; Lynn From; Urvi Mujumdar; Roberto Zanetti; Marianne Berwick
Journal:  Cancer Causes Control       Date:  2007-01-06       Impact factor: 2.506

2.  Risk Factors of Subsequent Primary Melanomas in Austria.

Authors:  Christoph Müller; Judith Wendt; Sabine Rauscher; Raute Sunder-Plassmann; Erika Richtig; Ingrid Fae; Gottfried Fischer; Ichiro Okamoto
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

3.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

4.  Melanoma prevention: are we doing enough? A Canadian perspective.

Authors:  A M Joshua
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

Review 5.  A systematic review of health-related quality of life in cutaneous melanoma.

Authors:  D Cornish; C Holterhues; L V van de Poll-Franse; J W Coebergh; T Nijsten
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

6.  Barriers and facilitators of adherence to medical advice on skin self-examination during melanoma follow-up care.

Authors:  Annett Körner; Martin Drapeau; Brett D Thombs; Zeev Rosberger; Beatrice Wang; Manish Khanna; Alan Spatz; Adina Coroiu; Rosalind Garland; Gerald Batist
Journal:  BMC Dermatol       Date:  2013-03-01

7.  Different aspects of self-reported quality of life in 450 german melanoma survivors.

Authors:  Annika Waldmann; Sandra Nolte; Ron Pritzkuleit; Eckhard W Breitbart; Alexander Katalinic
Journal:  Cancers (Basel)       Date:  2011-05-11       Impact factor: 6.639

8.  Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014.

Authors:  Emily D Cai; Susan M Swetter; Kavita Y Sarin
Journal:  J Am Acad Dermatol       Date:  2018-10-01       Impact factor: 15.487

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.